Ocugen, Inc. (FRA:2H51)

Market Cap	400.18M +93.9%
Revenue (ttm)	4.58M +14.3%
Net Income	-54.56M
EPS	-0.19
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,250
Average Volume	36,857
Open	1.261
Previous Close	1.267
Day's Range	1.229 - 1.261
52-Week Range	0.470 - 1.691
Beta	n/a
RSI	44.48
Earnings Date	Mar 2, 2026

About Ocugen

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 95
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2H51

Financial Performance

In 2024, Ocugen's revenue was $4.06 million, a decrease of -32.82% compared to the previous year's $6.04 million. Losses were -$54.05 million, -14.31% less than in 2023.

Financial numbers in USD